ZAMBELLI ALBERTO

Belloni, S., Tiberio, P., De Sanctis, R., Magon, A., Santoro, A., Zambelli, A., et al. (2024). Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) [Altro] [10.1016/j.critrevonc.2024.104550]. Dettaglio

Cazzaniga, M., Pronzato, P., Amoroso, D., Bernardo, A., Biganzoli, L., Bisagni, G., et al. (2024). Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study. CANCERS, 16(1) [10.3390/cancers16010117]. Dettaglio

Birtolo, M., Pedersini, R., Palermo, A., Vena, W., Morenghi, E., Cristofolini, G., et al. (2024). Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 191(2), 116-124 [10.1093/ejendo/lvae086]. Dettaglio

De Sanctis, R., Tiberio, P., Jacobs, F., Gaudio, M., Benvenuti, C., Giordano, L., et al. (2024). Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer. THE ONCOLOGIST, 29(9), 1113-1119 [10.1093/oncolo/oyae101]. Dettaglio

De Sanctis, R., Bruzzi, P., Zambelli, A. (2024). Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al. ANNALS OF ONCOLOGY, 35(12 (December 2024)), 1201-1202 [10.1016/j.annonc.2024.08.2345]. Dettaglio